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Abstract
Purpose—Superparamagnetic iron oxide nanoparticles (IONPs) are being investigated for brain 
cancer therapy because alternating magnetic field (AMF) activates them to produce hyperthermia. 
For central nervous system applications, brain entry of diagnostic and therapeutic agents is usually 
essential. We hypothesized that AMF-induced hyperthermia significantly increases IONP blood–
brain barrier (BBB) association/uptake and flux.
Methods—Cross-linked nanoassemblies loaded with IONPs (CNA-IONPs) and conventional 
citrate-coated IONPs (citrate-IONPs) were synthesized and characterized in house. CNA-IONP 
and citrate-IONP BBB cell association/uptake and flux were studied using two BBB Transwell® 
models (bEnd.3 and MDCKII cells) after conventional and AMF-induced hyperthermia exposure.
Results—AMF-induced hyperthermia for 0.5 h did not alter CNA-IONP size but accelerated 
citrate-IONP agglomeration. AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP and 
citrate-IONP BBB cell association/uptake. It also enhanced the flux of CNA-IONPs across the two 
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in vitro BBB models compared to conventional hyperthermia and normothermia, in the absence of 
cell death. Citrate-IONP flux was not observed under these conditions. AMF-induced 
hyperthermia also significantly enhanced paracellular pathway flux. The mechanism appears to 
involve more than the increased temperature surrounding the CNA-IONPs.
Conclusions—Hyperthermia induced by AMF activation of CNA-IONPs has potential to 
increase the BBB permeability of therapeutics for the diagnosis and therapy of various brain 
diseases.
Keywords
alternating magnetic field; blood-brain barrier permeability; cross-linked nanoassemblies; flux; 
superparamagnetic iron oxide nanoparticles
Introduction
Brain capillary endothelial cells cooperate with pericytes, astrocytes, and neurons to 
generate the unique barrier properties of the blood–brain barrier (BBB), which is part of the 
neurovascular unit that plays a crucial role in safeguarding the brain from potentially 
harmful endogenous and exogenous substances circulating in the blood. The BBB, with its 
tight junctions and efflux transporters, restricts the entry of most therapeutic agents, 
frequently resulting in unsuccessful treatment of brain diseases (1). Because of this 
challenge, research efforts have focused for decades on the development of strategies to 
more effectively deliver drugs to the central nervous system (CNS). A promising approach 
to overcome limited drug flux into the CNS is the employment of multifunctional 
nanoparticles (2). Numerous studies have shown that nanoparticle uptake into brain 
parenchyma can occur through receptor-mediated endocytosis, absorptive transcytosis, and 
tight junction opening (3,4). However, many in vivo reports of nanoparticle CNS 
applications, particularly those of metal-based nanoparticles, showed only indirect evidence 
of flux across the BBB into brain parenchyma. Given the distance between microvessels in 
the brain is less than 20 μm (e.g. see (5)), to be able to definitively state that a nanomaterial 
has crossed the in vivo BBB requires a high resolution imaging method, such as electron 
microscopy or confocal laser scanning microscopy, or a separation method such as described 
by Triguero et al. (6). Many reports concluded the nanomaterial entered the brain based on 
elemental analysis, fluorescence, or radioactivity using detection methods that do not 
differentiate substances in the vascular compartment of the brain or associated with the BBB 
vs. brain parenchyma, such as elemental analysis, e.g. (7), radioactivity, e.g. (8), or based 
their conclusions only on therapeutic efficacy in an animal model (9). The ability of 
nanoparticles to distribute from the luminal to the basolateral sides of the BBB or blood-
tumor barrier will determine whether they can deliver drugs to specific brain tissues, such as 
brain tumors. A better understanding of nanoparticle association/uptake with, and flux 
across, biological barriers including the highly regulated BBB, is urgently needed.
Superparamagnetic iron oxide nanoparticles (IONPs) are useful to provide insights into 
these issues as well as having diagnostic and therapeutic applications. They can be activated 
by an alternating magnetic field (AMF) to generate local hyperthermia (10). Iron oxide 
nanoparticles are known to generate heat due to molecular vibration under AMF. The 
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mechanisms underlying the production of heat for nanoparticles of the size utilized in this 
study (<50 nm) include the Neel mode (rotation of the magnetic moment of the IONPs away 
from its crystal lattice toward the alternating magnetic field to minimize its potential energy, 
providing internal friction due to the movement of the magnetic moment) and rotational 
friction provided by the viscous drag of the suspending medium as the IONPs align with the 
magnetic field. Mild hyperthermia (40 to 44°C) is cytotoxic to tumor cells (11). AMF 
activation of IONPs leads to a localized hyperthermia resulting in brain cancer cell death in 
vitro and in vivo (12,13). Mild whole body hyperthermia can increase BBB permeability, 
which has potential for brain therapeutic application (14). Whole body hyperthermia (42°C 
for 0.5 h) significantly increased flux of doxorubicin delivered in a temperature-sensitive 
liposome across the BBB in vitro and in vivo (15). However, whole body hyperthermia led 
to heat stress and caused CNS toxicity, including edema (14,16). One possibility is to 
develop an IONP nanocarrier system which can generate local hyperthermia to increase 
BBB permeability and brain accumulation for potential CNS diagnostic and therapeutic 
applications. Whether the BBB permeability of IONPs can be enhanced by taking advantage 
of their unique superparamagnetic properties, such as AMF-induced hyperthermia, needs to 
be investigated.
There are few reports of IONP association/uptake with, and flux across, the BBB. A recent 
study evaluated the uptake transport of surface-modified IONPs by human-derived 
endothelial cells; no IONP flux across the cells was observed (17). The lack of IONP flux 
across the BBB limits their applications to target the brain for diagnostic and therapeutic 
applications.
In this study, conventional citrate-coated IONPs (citrate-IONPs) and cross-linked 
nanoassemblies loaded with IONPs (CNA-IONPs) (10) were used as IONP nanocarrier 
models to investigate the effect of AMF-induced hyperthermia on IONP permeability and 
flux across the BBB.
Citrate-IONPs were prepared by co-precipitating ferric and ferrous ions in the presence of 
ammonium hydroxide with citric acid as a stabilizer, while CNA-IONPs were prepared by 
forming IONPs inside the core of poly(ethylene glycol)-poly(aspartate) block copolymer 
cross-linked nanoassemblies. Our previous research showed that CNA-IONPs are stable for 
30 h in cell culture medium in the absence and presence of AMF (10). No cytotoxicity was 
seen in mouse brain endothelial-derived (bEnd.3) cells exposed to ≤10 mg/mL CNA-IONPs 
for 30 h (10). Incorporating IONPs in CNAs significantly improved particle stability and 
biocompatibility compared to citrate coating, providing a promising IONP formulation. 
Citrate-IONPs, as one of the most common and commercially available IONPs, were used as 
a control.
The objective of this study was to determine the potential effect and mechanism of AMF-
induced hyperthermia on IONP association/uptake with, and flux across, BBB models. We 
evaluated citrate-IONP and CNA-IONP association/uptake, flux across, and effects using 
two in vitro BBB models (bEnd.3 and Madin-Darby canine kidney II (MDCKII) cells) in 
Transwells®. Although bEnd.3 cells form tighter junctions than some other BBB-derived 
cell lines, such as bEnd.5 cells and mouse brain endothelial cell 4 (18), the confluent bEnd.3 
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cell monolayer does not recapitulate the degree of tightness of in vivo BBB junctions, which 
is typical for BBB models composed of only BBB-derived endothelial cells (19). The bEnd.
3 cell layer model better represents the clinically relevant blood-tumor barrier than the BBB. 
To study a better BBB model, we also used MDCKII cells, a non-cerebral-derived cell line, 
because they express the components of the BBB tight junctions, are known to form tight 
junctions very well (20,21), and have been used as a surrogate in vitro BBB model (22). 
Results of this study provide a better understanding how AMF-induced hyperthermia 
influences IONP cell association/uptake and flux across the BBB, which will be beneficial 
for improving their CNS applications, such as brain tumor diagnosis and therapy.
Materials and Methods
Materials
The chemicals used to prepare the citrate-coated IONPs (citrate-IONPs) and cross-linked 
nanoassemblies loaded with superparamagnetic iron oxide nanoparticles (CNA-IONPs) have 
been described (10). The immortalized mouse brain endothelial cell line bEnd.3 (American 
Type Culture Collection, Manassas, VA) and MDCKII cells (European Collection of Cell 
Cultures, Salisbury, UK) were used. Dulbecco's Modified Eagle Medium (DMEM) and 
minimum essential medium with Earle's salts (MEM) were obtained from Mediatech, 
Manassas, VA. Fetal bovine serum (FBS) was obtained from Atlanta Biologicals, 
Lawrenceville, GA. Penicillin and streptomycin were obtained from Invitrogen, Grand 
Island, NY. Transwell® filters were obtained from Corning Costar, Lowell, MA. Ferrozine 
and neocuproine were obtained from the Hach Company, Loveland, CO. Lucifer yellow was 
obtained from Sigma-Aldrich, St. Louis, MO. Bicinchoninic acid assay kits (BCA Protein 
Assay Kits) were obtained from Thermo Fisher Scientific, Waltham, MA. Twelve well 
plates were obtained from BD Falcon, San Jose, CA.
Preparation and Characterization of Citrate-IONPs and CNA-IONPs
Citrate-IONPs and CNA-IONPs were synthesized and characterized as described (10,23). 
Briefly, citrate-IONPs were prepared by adding ammonium hydroxide dropwise to a mixture 
of ferric chloride hexahydrate (Fe3+) and ferrous chloride tetrahydrate (Fe2+) dissolved in 
deionized water (Fe3+:Fe2+ = 2:1) under a nitrogen atmosphere at 85°C and then stabilizing 
the IONPs with citric acid (2 equivalents). The citrate-IONPs were collected by a magnet 
and washed repeatedly using ethanol prior to overnight vacuum drying. CNA-IONPs were 
prepared by a similar method, replacing citric acid with cross-linked poly(ethylene glycol)-
poly(aspartate) block copolymer nanoassemblies comprising 5 kDa PEG and 40 repeating 
units of aspartate that were chemically conjugated with 1,8-diaminooctane. In contrast to 
citrate-IONPs, CNA-IONPs dispersed in water stably, and were thus purified by filtration 
and dialysis prior to freeze drying. Both citrate-IONPs and CNA-IONPs were prepared in 
bulk, stored in powder forms at −20°C, and reconstituted in aqueous solutions (PBS or cell 
culture medium) immediately before use. Their particle size was measured each time by 
DLS. The stability of citrate-IONPs (0.05 mg/mL) and CNA-IONPs (2.5 mg/mL) in the cell 
culture media described below was monitored for 6 h after 0.5 h exposure to 37°C, 43°C, or 
AMF using dynamic light scattering (DLS) analysis (90Plus NanoParticle size distribution 
analyzer, Brookhaven Instruments, Holtsville, NY).
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Cell Lines and Culture Conditions
bEnd.3 and MDCKII cells were cultured in DMEM and MEM with 10 and 5% FBS, 
respectively, and 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified 
incubator with 5% CO2. They were used from passages 5 through 10 and 45 through 60, 
respectively.
Transwell® Cultures
bEnd.3 and MDCKII cells were seeded on Transwell® filters (4.67 cm2 for the 6-well 
polycarbonate plate, pore size 3.0 μm) at a density of 200,000 cells/cm2, and grown to a 
monolayer (Fig. 1). bEnd.3 assays were performed 7 to 10 days after seeding (24), when 
transendothelial electrical resistance was >120 Ω·cm2, measured using a RMA321-Millicell-
ERS voltohmmeter (Millipore Corp, Billerica, MA). The apparent permeability coefficient 
(Papp) of LY at 37°C was 3.81±0.17× 10−6 cm/s (Table I), similar to a previous report (24). 
MDCKII assays were performed 4 days after seeding (25), when resistance was >170 
Ω·cm2.
Ferrozine Iron Assay
The iron content of the nanoparticle dispersions, cell culture media, nanoparticle-loaded 
cells, and control cells was determined using a ferrozine assay (26,27). Fifty μL of 
appropriately diluted sample was mixed with 50 μL of 1.4 mM HCl and 20 μL 2 M ascorbic 
acid and incubated at 70°C for 1 h. After cooling to room temperature, 30 μL of iron 
detection reagent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate, and 1 
M ascorbic acid in water) was added. After 30 min, the solution in each tube was transferred 
into a well of a 96 well plate and absorbance measured at 550 nm on a microplate reader. A 
standard curve was prepared with 0, 0.1, 0.2, 0.5, 1, 2, 5, and 10 μg/mL iron, and similarly 
treated.
AMF-Induced Heating Profiles
The heating profiles of AMF-activated CNA-IONPs (2.5 mg/mL) were evaluated in the 
Transwell® cell model. The heating profile for citrate-IONPs was not studied because our 
previous study showed that 0.05 mg/mL IONPs provide insufficient iron to increase the cell 
culture medium temperature and higher concentrations kill the cells (10). AMF was induced 
by a Taylor Winfield induction power supply (Taylor-Winfield Technologies 
MMF-3-135/400-2, Columbus, OH) equipped with a 15 mm diameter, 5 turn solenoid. The 
AMF field parameters were 33.4 kA/m at 300 kHz. The temperature of the medium in the 
Transwell® donor chamber was measured every 0.25 s using a Fluoroptic® thermometer 
(LumaSense Technologies, Santa Clara, CA). The initial medium temperature was 37°C.
Paracellular Flux
To measure paracellular pathway permeability, 100 μM LY was added to the Transwell® 
donor side medium in every flux study. Media samples (100 μL) from the donor chamber 
were collected at time zero and from the receiving chamber at different times for LY 
quantification. LY concentration was measured in the donor and receiving chamber at the 
end of each experiment. Fluorescence was determined in a SpectraMax M5 Multi-Mode 
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Microplate Reader (Molecular Devices, Sunnyvale, CA) at λex/λem = 450/530 nm and 
compared with a standard curve with a linear range from 0.5 to 30 μM in DMEM (bEnd.3 
cells) or MEM (MDCKII cells) (28).
Citrate-IONP and CNA-IONP Cell Association/Uptake and Flux Using bEnd.3 and MDCKII In 
Vitro BBB Models
Citrate-IONPs (0.05 mg/mL) or CNA-IONPs (2.5 mg/mL) and 100 μM LY were introduced 
into the Transwell® donor chamber. The concentrations were based on results of our 
previous cytotoxicity study (10). To determine cell association/uptake the cells were 
exposed to 37 or 43°C (the latter to compare to AMF-induced hyperthermia) or AMF for 0.5 
h. All were then maintained at 37°C for 6 h. IONP cell association/uptake was terminated by 
medium removal and addition of ice cold solution containing 137 mM NaCl and 10 mM 
HEPES at pH 7.4 (29). Cells were trypsinized using 0.25% trypsin-EDTA for 5 min at 37°C 
and the suspension centrifuged. The cell pellet was re-suspended with medium. A trypan 
blue exclusion test was performed to assess cell viability (30). Protein concentrations were 
measured using the BCA Protein Assay Kit. At least three replications of the cell 
association/uptake experiments were conducted. To determine CNA-IONP flux across the 
MDCKII in vitro BBB model, CNA-IONPs (2.5 mg/mL) and LY were added to the donor 
chamber medium. The cells were incubated for 0.5, 1, 2, or 4 h at 43°C or exposed to 0.5 h 
AMF-induced hyperthermia followed by incubation at 37°C for 6 h. These experiments were 
performed in triplicate wells and repeated once in triplicate wells.
Citrate-IONP and CNA-IONP Cell Localization Using Transmission Electron Microscopy
bEnd.3 and MDCKII cells were seeded on 12 well plates at a density of 200,000 cells/cm2. 
A cell association/uptake experiment was performed 3 days after seeding. The cells were 
exposed to cell culture medium containing 0.05 mg/mL citrate-IONPs or CNA-IONPs for 2 
h, and then quickly washed with ice cold saline 3 times. The cells were fixed in 3.5% 
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 for 1 h at 4°C. Samples were dehydrated 
in ascending concentrations of ethanol and embedded in Eponate 12. After polymerization, 
blocks were sectioned at 80 nm and viewed with a Philips Tecnai 12 Biotwin electron 
microscope (FEI, Hillsboro, OR).
Data and Statistical Analysis
The apparent permeability coefficient (Papp) of LY and CNA-IONPs and their influx rates 
were calculated by linear regression. The Papp (in cm/s) was calculated using the equation: 
Papp=(ΔQ/Δt)/(area*CD) (25). ΔQ/Δt is the linear appearance rate obtained from the profile 
of the transported amount of the substrate against time (mg/s). Area is the surface area of the 
cell monolayer (4.67 cm2 for a 6-well plate). CD is the initial donor concentration of LY or 
nanoparticle (mg/mL). Results from the first 6 h of flux data were used when the linear 
regression R2 was >0.8. The % of IONPs /LY in receiving chamber = mass amount of 
IONPs/LY in the receiving chamber at certain time point × 100%/initial donor dose. Mass 
balance of LY = (LY in the receiving and donor chambers) × 100%/initial donor dose. 
Bartlett's test was used to determine if samples had equal variances. One-way ANOVA 
followed by Tukey's test was used to test for significant differences between citrate-IONP 
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and CNA-IONP cell association/uptake and apparent permeability coefficients among the 
treatment groups. Two-way ANOVA followed by the Bonferroni multiple comparisons 
procedure was used to identify significant flux differences among the treatment groups and 
times using GraphPad Prism. The results of the statistical analysis for one-way and two-way 
ANOVAs are reported as F(df effect, df error) = F-value and P-value. All statistical tests 
were conducted using GraphPad Prism (GraphPad Software, San Diego, CA). All results are 
reported as mean±standard deviation (SD). Statistical significance was accepted at p<0.05.
Results
Characterization of Citrate-IONP and CNA-IONP Size, Stability, and AMF Response
Citrate-IONPs had a primary particle size of ∼10 nm, were 90±10 nm in water at 0.2 
mg/mL, but agglomerated to >400 nm and precipitated in PBS and cell culture medium (10). 
This agglomeration was accelerated by conventional (43°C) and AMF-induced 
hyperthermia, resulting in >800 nm agglomerates (results not shown).
The CNA-IONPs were 25±3 nm measured by DLS. IONP loading of CNAs was 25±3 and 
25±1 wt % determined by thermogravimetric analysis and inductively coupled plasma mass 
spectrometry analysis, respectively. AMF-induced hyperthermia had no effect on CNA-
IONP size in cell culture medium at 30 h (Fig. 2a). AMF activation of CNA-IONPs (2.5 
mg/mL) in cell culture medium increased the medium temperature to 41°C in 10 min (Fig. 
2b).
Citrate-IONP and CNA-IONP Association/Uptake and Flux Using a bEnd.3 In Vitro BBB 
Model
Citrate-IONP cell association/uptake significantly increased in the conventional 
hyperthermia and AMF-induced hyperthermia groups compared to control (F(2,6) = 24, 
P<0.0014) (Fig. 3a). In contrast, analysis of iron concentration showed CNA-IONP cell 
association/uptake did not change significantly in the conventional hyperthermia or the 
AMF-induced hyperthermia groups compared to the 37°C controls (Fig. 3b). TEM 
observations provided insight into the different cell association/uptake iron levels. 
Agglomerated citrate-IONPs (close to micrometer size) (Fig. 4a) with their primary size 
around 10 nm (Fig. 4b) were observed inside bEnd.3 cells. After analysis of three separately 
prepared TEM samples and two sections from each sample, CNA-IONPs were occasionally 
found in three samples (Fig. 4c). CNA-IONP cell association was at least 10 times lower 
compared with citrate-IONPs (Fig. 3b vs. a; Fig. 4c vs. b).
Flux of citrate-IONPs through the bEnd.3 monolayer did not increase over 6 h and was 
similar among the three treatment groups (Fig. 3c). The flux of CNA-IONPs significantly 
increased from 1 to 6 h in the AMF-induced hyperthermia group compared with the control 
and conventional hyperthermia groups (Fig. 3d). The paracellular flux rates measured by LY 
were linear for the first 6 h in the presence of citrate-IONP- (Fig. 3e) and CNA-IONP- (Fig. 
3f) treated groups. Mass balance of LY for the bEnd.3 model was between 89 and 112%. 
Paracellular flux of LY in the CNA-IONP treated group, but not the citrate-IONP-treated 
group, was significantly increased in the AMF-induced hyperthermia group from 2 to 6 h 
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(Fig. 3e and f). The Papp of LY was similar in the control and conventional hyperthermia 
groups in the presence of citrate-IONPs and CNA-IONPs (Fig. 3e and f; Table I). However, 
the Papp of CNA-IONPs in the AMF-induced hyperthermia group significantly increased 
(148%; F(2,7) = 19, P<0.0016), and LY to a lesser extent (90%; F(2,7) = 280, P<0.0001), 
compared with the normothermic control group (Table I). The trypan blue exclusion test 
showed no cell death in any experiments (results not shown). Since the flux was linear only 
for the first 6 h, the rest of this study only observed the flux rate for 6 h.
Effect of AMF-Induced vs. Conventional Hyperthermia on CNA-IONP Cell Association/
Uptake and Paracellular Flux Using a MDCKII In Vitro BBB Model
In the absence of AMF-induced hyperthermia, CNA-IONP and LY flux were temperature- 
and concentration-independent in the MDCKII in vitro BBB model (Fig. 5). Total flux was 
<0.2% over 6 h. MDCKII cell association/uptake of CNA-IONPs was significantly 
increased in the AMF-induced hyperthermia group compared to the control and 
conventional hyperthermia groups (F(2,7) = 10, P<0.0081) (Fig. 6a). AMF-induced 
hyperthermia significantly increased CNA-IONP flux (Fig. 6b). The Papp of CNA-IONPs 
(F(2,7) = 27, P<0.0005) increased much more than LY (F(2,7) = 7, P<0.019) in the AMF 
group, 128% and 20%, respectively, compared with controls (Table I). The trypan blue 
exclusion test showed no cell death in any experiments (results not shown). Lucifer yellow 
Papp was 0.49±0.03×10−6 cm/s at 37°C (Table I). The LY Papp was 0.46 to 0.50×10−6 cm/s 
for the first 6 h after 0.5, 1, and 2 h exposure at 43°C followed by 37°C for 6 h. However, 
after incubation at 43°C for 4 h, the Papp of LY significantly increased 22% (Papp, 
0.61±0.05× 10−6 cm/s) compared with the normothermic control and similar to the LY Papp 
across MDCKII cells 6 h after exposure to AMF-induced hyperthermia for 0.5 h (Table I). 
Paracellular flux (LY) was significantly greater across the MDCKII cells starting 2 h after 
exposure to AMF-induced hyperthermia (0.5 h) compared with the control and conventional 
hyperthermia (Fig. 6c). Mass balance of LY for the MDCKII model was between 92 and 
108%. The trypan blue exclusion test did not reveal cell death in any experiments after cell 
exposure to 43°C for 4 h, or AMF-induced hyperthermia for 0.5 h, followed by 6 h at 37°C 
(results not shown).
Discussion
Biocompatibility and stability in biological environments, such as cell culture medium or 
blood, are crucial for nanoparticles to serve as good candidate carriers across the BBB 
(31,32). In this study, we investigated citrate-IONP and CNA-IONP association/uptake, flux 
across, and effects on two in vitro models of the BBB under normothermic, conventional 
hyperthermic, and AMF-induced hyperthermic conditions. Citrate-IONPs agglomerated very 
rapidly in cell culture medium to >400 nm (10). Increased temperature enhanced their 
agglomeration. Even though citrate-IONPs agglomerated close to micrometer size in vitro, 
they were still able to be taken up by BBB cells. The TEM results suggested that citrate-
IONPs were taken up by endocytosis. Citrate-IONPs did not show increased flux across 
bEnd.3 cells over 6 h, nor did increased temperature induced by conventional hyperthermia 
or AMF increase citrate IONP flux across bEnd.3 cells. Our results demonstrated that 
citrate-IONPs can enter BBB cells through an endocytosis pathway, however, they did not 
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cross the in vitro BBB model. No transcytosis of citrate-IONPs across the BBB suggests 
they lack potential therapeutic CNS applications.
CNA incorporation of IONPs improved its stability (size ∼25 nm, Fig. 2a) and 
biocompatibility compared to citrate IONPs, without loss of AMF-induced hyperthermia 
properties (10). Our previous research demonstrated that CNAs prepared from 
biocompatible poly(ethylene glycol)-poly(aspartate) [PEG-p(Asp)] block copolymers 
provided stability for nanoparticles, by entrapping them in the core of a charged cage 
produced by locally highly concentrated carboxylate groups that isolate the CNAs and 
stabilize them from interaction among themselves and environmental cations. CNAs provide 
the ability to incorporate hydrophobic and amphiphilic payloads without changing particle 
size (23,33). CNA-IONP flux increased with time across bEnd.3 cells at 37°C, resulting in 
flux of less than 5% in 6 h. Flux across MDCKII cells was less than 0.2%. We also 
demonstrated that CNA-IONP flux was concentration independent, providing evidence that 
it was through a non-diffusion mechanism (Fick's law). More studies are needed to 
investigate the mechanisms of IONP flux across the BBB. This very limited IONP flux is 
consistent with a report of charged IONP flux using a human brain derived BBB model, in 
which they did not observe any IONP flux over 24 h (17). The Papp (0.05 to 1× 10−8 cm/s) 
of eleven iron oxide 200 to 1100 nm particles investigated using a bEnd.3 BBB model 
marginally supported the conclusion that larger particles have increased difficulty crossing 
the BBB (34). The Papp of CNA-IONPs is at least 10 times higher than these results. CNA-
IONPs, with a relatively stable size <40 nm in cell culture medium, showed their greater 
ability to cross the BBB than other IONP carriers.
AMF-induced hyperthermia doubled the Papp of CNA-IONPs in the bEnd.3 model during 
the first 6 h. Ten percent of CNA-IONPs crossed the bEnd.3 monolayer within 6 h. The LY 
flux was also significantly increased, providing evidence that AMF-induced hyperthermia in 
the presence of CNA-IONPs opened the paracellular pathway to increase CNA-IONP flux. 
The lack of observed cell death ruled that out as the cause of increased flux. The cell uptake/
association of CNA-IONPs was ∼10 times lower than citrate-IONPs. The low cell uptake of 
CNA-IONP was consistent with CNA-IONPs crossing the BBB mainly through the 
paracellular pathway after AMF-induced hyperthermia in the bEnd.3 in vitro BBB model. A 
recently published study also demonstrated that a static externally-applied magnetic field 
can increase IONP permeability through the paracellular pathway of bEnd.3 cells in vitro 
(35). The present report is the first to show that AMF-induced hyperthermia significantly 
increases CNA-IONP flux across in an in vitro BBB model with low toxicity. AMF-induced 
hyperthermia mediated by IONPs is one approach to potentially increase IONP BBB 
permeability and flux for CNS diagnosis and therapy.
The Papp of LY across MDCKII cells exposed to AMF increased only 20% compared to 
controls, whereas flux increased 90% in the bEnd.3 model. AMF-induced hyperthermia 
increased the Papp of CNA-IONPs 148% in the bEnd.3 model and 128% in the MDCKII 
model. In general, a similar trend was observed in BBB permeability changes (LY flux) 
induced by AMF-induced hyperthermia using the two in vitro BBB models. However, the 
‘leaky’ bEnd.3 Transwell® model's paracellular pathway flux was more sensitive to 
conventional and AMF-induced hyperthermia than MDCKII cells. Previous studies also 
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showed a threshold at 43°C for BBB disruption induced by conventional hyperthermia in 
normal brain tissue (36,37). However, in a leaky BBB, such as the blood-tumor barrier 
which was more sensitive to conventional hyperthermia, permeability increased at a lower 
temperature (38). The bEnd.3 Transwell® model can provide insight into the effect of AMF-
induced hyperthermia on leaky BBB conditions such as the blood-tumor barrier. Even 
though MDCKII cells are not a BBB-derived cell line, they were shown to be a good in vitro 
model to predict the extent of brain exposure and the rate of brain association/uptake in vivo 
for several CNS drug candidates (39). However, there are major differences between 
MDCKII epithelial and brain endothelial cells, such as expression of different transporters 
(40). Comparing these two in vitro BBB models, the MDCKII cell model better predicts 
whether AMF-induced hyperthermia changes paracellular flux in normal brain tissue 
because they form tighter junctions than the bEnd.3 cells. Because of the unique 
physicochemical properties and different cell association/uptake mechanisms of 
nanoparticles compared with small drug candidates, further studies were needed to 
investigate the correlation between nanoparticle flux across the bEnd.3 and MDCKII 
Transwell® models and the BBB in vivo.
The potential application of conventional hyperthermia to increase BBB permeability has 
been investigated for decades. Numerous studies showed that conventional hyperthermia can 
increase BBB permeability depending on heat magnitude and duration (14,16). However, 
the difference between conventional hyperthermia and AMF-induced hyperthermia on BBB 
permeability has not been well studied. The Papp of LY and CNA-IONPs significantly 
increased (90 and 148% respectively) in the AMF-induced hyperthermia group compared 
with the conventional hyperthermia group bEnd.3 cells. There was no significant difference 
between the 37 and 43°C groups, suggesting AMF-activation of CNA-IONPs increased 
BBB permeability not only by simple heating but also other factors such as IONP vibration 
or difference in IONP surface temperature vs. the surrounding temperature. CNA-IONPs can 
bind to the cell surface and vibrate under AMF, mechanically increasing BBB permeability. 
Other research demonstrated that cell surface bound IONPs can mechanically activate 
certain cell surface receptors (41). The temperature we measured was the environmental 
temperature in the Transwell® medium rather than the IONP surface temperature. Previous 
research showed that IONP surface temperature can be up to 20°C higher relative to the 
surrounding regions (42). Further research needs to be conducted to investigate how CNA-
IONPs associate with BBB cells and the role of temperature and mechanical effects on BBB 
permeability.
AMF-induced hyperthermia can increase paracellular permeability more effectively than 
conventional hyperthermia. Our results showed that conventional hyperthermia (43°C) did 
not influence paracellular flux up to 2 h and that flux significantly increased at 43°C after 4 
h. A previous whole body hyperthermia study with rats also showed BBB permeability 
changes were highly dependent on heat magnitude and duration. No BBB permeability 
change was observed (within 2 h) under whole body hyperthermia, but BBB permeability 
increased after 4 h whole body hyperthermia (16). We did not observe any cell death even 
after 4 h conventional hyperthermia at 43°C. However, whole body hyperthermia leads to 
heat stress causing numerous CNS toxicities such as edema and neuropil damage (43). Our 
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results also showed that the Papp of LY after conventional hyperthermia at 43°C for 4 h was 
similar to the Papp of LY at AMF-induced hyperthermia for 0.5 h. AMF-induced 
hyperthermia can increase BBB permeability similar to conventional hyperthermia at a 
lower cell medium temperature and shorter time without cell death in vitro. Previous 
research showed that 0.5 h AMF-induced hyperthermia killed head and neck cancer cells in 
mice without harming normal cells (44). Furthermore, previous research also demonstrated 
that AMF-induced hyperthermia only led to a transient BBB permeability increase in vivo. 
Their results showed that 0.5 h AMF-induced hyperthermia can increase the BBB 
permeability transiently and the BBB permeability recovered 2 h after hyperthermia 
treatment in mice (45). In the present stu dy AMF-induced hyperthermia showed the 
potential advantages of transiently increased BBB permeability and reduced toxicity 
compared with conventional hyperthermia, potentially increasing the brain targeting of 
IONPs and their pharmacotherapeutic efficacy.
Conclusions
CNA-IONPs showed stability in a mammalian tissue (cell culture) relevant medium. Flux 
across bEnd.3 and MDCKII in vitro BBB models was low under normothermic conditions. 
AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP cell association/uptake and flux 
in the absence of cell death. In contrast, citrate IONPs agglomerated in cell culture medium 
and were taken up by, but did not flux through, the bEnd.3 BBB model. AMF-induced 
hyperthermia enhanced the BBB association/uptake and permeability of CNA-IONPs more 
effectively than conventional hyperthermia, by mechanisms in addition to elevated 
temperature around the IONPs. CNA-IONPs activated by AMF can produce a quantifiable, 
controllable hyperthermia in a defined area which is required for clinical applications. AMF-
induced hyperthermia provides an approach to deliver IONPs across the BBB with low 
toxicity for potential therapeutic and diagnostic CNS applications.
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Abbreviations
AMF Alternating magnetic field
BBB Blood–brain barrier
bEnd.3 A transformed murine brain/cerebral cortex endothelial cell line
Citrate IONPs Citrate iron oxide nanoparticles
CNA-IONPs Cross-linked nanoassembly iron oxide nanoparticles
CNS Central nervous system
DLS Dynamic light scattering
IONPs Iron oxide nanoparticles
LY Lucifer yellow
MDCKII Madin-Darby canine kidney II cells
Papp Apparent permeability coefficient
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Fig. 1. 
Schema of the Transwell® system and AMF used for cell association/uptake and flux 
studies.
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Fig. 2. 
AMF did not change CNA-IONP nanoparticle size but produced hyperthermia. Particle 
stability characterization results determined by DLS after exposure to 37°C for 30 h (n=6), 
43°C (0.5 h) followed by 37°C for 30 h (n=6), or AMF (0.5 h), followed by 37°C for 30 h 
(n=4) (a). Representative heating profile of CNA-IONPs in cell culture medium for fine-
tuned remote heating with 0.5 h application of AMF (b). Cell culture medium exposed to 
AMF that contained no CNA-IONPs (37°C) served as the control.
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Fig. 3. 
Citrate-IONP and CNA-IONP cell association/uptake and flux across bEnd.3 cells. Citrate-
IONP bEnd.3 cell association/uptake after 37°C for 6 h (n=3), conventional hyperthermia at 
43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF-induced hyperthermia (0.5 h) 
followed by 37°C for 6 h (n=3) (a). CNA-IONP bEnd.3 cell association/uptake after 37°C 
for 6 h (n=3), conventional hyperthermia at 43°C (0.5 h) followed by 37°C for 6 h (n=3), or 
AMF-induced hyperthermia (0.5 h) followed by 37°C for 6 h (n=4) (b). Citrate-IONP flux 
across bEnd.3 cells (c). CNA-IONP flux across bEnd.3 cells (d). The paracellular flux 
across bEnd.3 cells measured by LY for the first 6 h in the Citrate-IONP treated group (e) 
and CNA-IONP treated group (f). Error bars not seen in panels C, D, E, and F are less than 
the symbol height. * Significantly different compared to 37°C in panel A or compared to 
37°C and conventional hyperthermia in panel D and panel F.
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Fig. 4. 
Citrate IONP and CNA-IONP cell localization. Transmission electron microscopy results of 
the cellular localization of the Citrate-IONPs (a and b) and CNA-IONPs (c) in bEnd.3 cells 
at 2 h. The arrows indicate the location of IONPs inside the cells.
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Fig. 5. 
Paracellular permeability and CNA-IONP flux across the MDCKII in vitro BBB model. LY 
(a) and CNA-IONP (b) flux at 2 concentrations and 2 temperatures (n=3).
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Fig. 6. 
CNA-IONP cell association/uptake and CNA-IONP and Lucifer yellow flux across 
MDCKII cells. CNA-IONP MDCKII cell association/uptake after 37°C for 6 h (n=3), 
conventional hyperthermia at 43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF-induced 
hyperthermia (0.5 h) followed by 37°C for 6 h (n=4) (a). CNA-IONP flux across a MDCKII 
in vitro BBB model (b). The effect of conventional and AMF-induced hyperthermia on LY 
flux across MDCKII cells after 43°C incubation (n=3) or AMF for 0.5 h followed by 37°C 
for 6 h (n=4), compared to 37°C control (n=3) (c). * Significantly different compared to 
AMF (0.5 h) in panel A or compared to 37°C and conventional hyperthermia in panels B 
and C.
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Table I
Lucifer Yellow and CNA-IONP Apparent Permeability Coefficients
Cell Type Sample 37°C 43°C (0.5 h) AMF (0.5 h)
bEnd.3 Lucifer yellow 3.81 ±0.17 4.04 ±0.14 7.25 ±0.28 *
CNA-IONPs 0.67 ±0.09 0.67 ±0.09 .66 ±0.37 *
MDCKII Lucifer yellow 0.49 ±0.03 0.49 ±0.049 0.59 ±0.04 *
CNA-IONPs 0.057 ±0.008 0.056 ±0.01 0.13 ±0.02 *
The table shows apical-to-basolateral Papp coefficients of LYand CNA-IONPs using bEnd.3 and MDCKII in vitro BBB models at 37°C for 6 h 
(n=3), 43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF (0.5 h) followed by 37°C for 6 h (n=4). Papp values are shown as 10−6 cm/s
*
Significantly different compared to 37 and 43°C (P<0.05)
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